Role of melatonin in the treatment of depression

Depression remains a serious problem despite the continuous stream of researches on the problems of affective disorders and the emergence of new antidepressants. About 80% of inpatients with depression and 70% of outpatients with this condition complain of sleep disorders. There are presently a few...

Full description

Bibliographic Details
Main Author: O. V. Kotova
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2011-06-01
Series:Nevrologiâ, Nejropsihiatriâ, Psihosomatika
Subjects:
Online Access:https://nnp.ima-press.net/nnp/article/view/92
Description
Summary:Depression remains a serious problem despite the continuous stream of researches on the problems of affective disorders and the emergence of new antidepressants. About 80% of inpatients with depression and 70% of outpatients with this condition complain of sleep disorders. There are presently a few available hypotheses of the onset of depressive disorders. Prominent among them are neurotransmitter dysfunction hypotheses and chronobiological concepts (the presence of altered circadian rhythms mediated by melatonin). There is currently a wide range of drugs that are able to affect melatonin metabolism, amongst which there is agomelatine and fluvoxamine.
ISSN:2074-2711
2310-1342